Phase II Trial of SMO/ AKT/ NF2/CDK Inhibitors in Progressive Meningiomas with SMO/ AKT/ NF2/CDK Pathway Mutations
A071401 Cohorts NF2, CDKN2A, CDK4, CDK6, CCND1, CCND2, CCND3, and CCNE1 Cohort (Abemaciclib Cohort) are closed to new patient registration (Step 1) to abemaciclib cohort, effective October 3, 2022.
